Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen NV

www.qiagen.com

Latest From Qiagen NV

NIH, BARDA Seek Out New Point-Of-Care Diagnostics For RADx Program To Boost US COVID-19 Testing

The US National Institutes of Health and the Biomedical Advanced Research and Development Authority are asking manufacturers to provide new COVID-19 diagnostic candidates for NIH’s Rapid Acceleration of Diagnostics (RADx) program.

Policy Coronavirus COVID-19

COVID-19: Nanomix Wins BARDA Funding For Mobile Point-Of-Care Assay

The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.

Coronavirus COVID-19 Infectious Diseases

German COVID-19 Testing Rate The Envy Of Others, With Demand Set To Climb

Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”

Germany Policy

Thermo Fisher Announces Plan To Pay For Qiagen; Bernard Confirmed As Qiagen CEO

Thermo Fisher has priced an offering of $2.2bn senior notes to pay for its planned acquisition of Qiagen. The news comes the same week, Qiagen confirmed Thierry Bernard as permanent CEO following the departure of former leader Peer Schatz. 

Appointments Financing
See All

Company Information

UsernamePublicRestriction

Register